Nilesh Bhatt

Nilesh Bhatt

Auto-generated profile, based on publicly available information

Nilesh Bhatt

Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
EPErica Parker
Erica Parker
MJMelinda A. Judge
Melinda A. Judge
EMEusebio Macete
Eusebio Macete
TNTacilta Nhampossa
Tacilta Nhampossa
JDJienchi Dorward
Jienchi Dorward
PSPeter N. Le Souëf
Peter N. Le Souëf
The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice and correspondence.

25 February 2020 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
CMCarla M. Madeira
Carla M. Madeira
KAKhalide I. Azam
Khalide I. Azam
DSDaisy N. Sato
Daisy N. Sato
Celso KhosaCelso Khosa
Celso Khosa
NBNilesh Bhatt
Nilesh Bhatt
SVSofia Omar Viegas
Sofia Omar Viegas
Background: Mozambique is among the highest tuberculosis, tuberculosis–HIV and multidrug-resistant-tuberculosis burden countries. Although molecular technologies are available in-country, mycobacterial isolation through culture remains an important tool for tuberculosis diagnostics and drug susceptibility testing.Objective: We evaluated the use of the Ogawa-Kudoh (OK) mycobacterial culture, a simple technique, to isolate Mycobacterium tuberculosis in two health units, in Maputo City, Mozambique.Methods: From May to December 2014, 122 patient samples were collected in Chamanculo General Hospital and Polana Caniço General Hospital. The specimens were first tested in the health units using the OK method and afterwards shipped to the National Tuberculosis Reference Laboratory for mycobacterial culture using the NALC-NaOH-Citrate (NALC) decontamination method followed by inoculation in Lowenstein Jensen (LJ) solid media as the reference standard.Results: Among 107 samples with valid results, 98 (91.6%) had concordant results in both methods; 9 (8.4%) had discordant results. The contamination rate was 4.1% (5/122) for the OK and 9.0% (11/122) for the NALC/LJ methods. The sensitivity of OK was 80% (95% confident interval [CI]: 51.4–94.7) and the specificity was 94% (95% CI: 85.8–97.3). The degree of agreement between both methods was moderate (Kappa: 0.68; 95% CI: 0.48–0.89).Conclusion: The OK method showed satisfactory sensitivity and specificity. The method also had a lower contamination rate when compared to the NALC/LJ. Similar to other studies in resource-limited settings, our findings showed that the OK method can effectively be implemented in settings with limited laboratory capacity to isolate tuberculosis bacteria by culture for further testing.

5 January 2024 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
IMIvete Meque
Ivete Meque
NHNicole Herrera
Nicole Herrera
ANAmâncio Nhangave
Amâncio Nhangave
DMDórcia Mandlate
Dórcia Mandlate
RGRui Guilaze
Rui Guilaze
MGMichelle M. Gill
Michelle M. Gill
Background: In 2022, Mozambique introduced Dolutegravir 10mg (pDTG), as part of paediatric antiretroviral therapy for children weighing < 20 kg. Understanding real-world challenges during national rollout can strengthen health systems in resource-limited settings. Objectives: We described the transition rate to, and new initiation of, pDTG, viral load suppression (VLS) post-pDTG, and factors associated with VLS among children living with HIV. Method: We conducted a retrospective cohort study involving children aged < 9 years and abstracted data from clinical sources. We used logistic regression to assess VLS and pDTG initiation predictors. Results: Of 1353 children, 1146 initiated pDTG; 196 (14.5%) had no recorded weight. Post-pDTG switch, 98.9% (950/961) of children maintained the same nucleoside reverse transcriptase inhibitor backbone. After initiating Abacavir/Lamivudine+pDTG, 834 (72.8%) children remained on the regimen, 156 (13.6%) switched off (majority to Dolutegravir 50mg), 22 (1.9%) had ≥ 2 anchor drug switches; 134 (11.7%) had no documented follow-up regimen. Factors associated with pDTG initiation or switch were younger age (adjusted odds ratio [AOR] = 0.71 [0.63–0.80]) and a recorded weight (AOR = 55.58 [33.88–91.18]). VLS among the 294 children with a viral load (VL) test after ≥ 5 months post-pDTG was 75.5% (n = 222/294). Pre-pDTG VLS rate among treatment-experienced children was 56.5% (n = 130/230). Factors associated with VLS were older age (AOR = 1.18 [1.03–1.34]) and previous VLS (AOR = 2.27 [1.27–4.06]). Conclusion: Most eligible children initiated pDTG per guidelines, improving post-pDTG VLS. Challenges included unexplained switches off pDTG after initiation, low VL coverage and inadequate documentation in clinic records.

23 December 2025 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
MSMario Songane
Mario Songane
Boris Kevin TchoungaBoris Kevin Tchounga
Boris Kevin Tchounga
RMRose Otieno Masaba
Rose Otieno Masaba
TDTatiana KATCHO DJIKEUSSI
Tatiana KATCHO DJIKEUSSI
JNJames Ndimbii
James Ndimbii
SMSushant Mukherjee
Sushant Mukherjee
Introduction: Understanding costs associated with identification of emerging infections is critical to inform the policy. Nested within a randomised controlled trial that found that a test-all (TA) model for rapid SARS-CoV-2 testing identified more SARS-CoV-2 cases than the standard screen-and-test (ST) model. Our study assessed the cost-effectiveness of integrating SARS-CoV-2 services into maternal, neonatal and child health (MNCH), HIV and tuberculosis (TB) clinics using the two models in Cameroon and Kenya. Methods: The total costs of implementing the TA and ST models in Cameroon and Kenya were estimated from a health systems perspective using a micro-costing method. The cost per client tested (CPCT) and tested positive (CPCTP) for SARS-CoV-2 were estimated by dividing the total cost of each model by the number of clients tested and tested positive, respectively. A decision tree and cost-effectiveness acceptability curve were used to compare the cost-effectiveness of the two models. Results: In Cameroon, the total cost of the TA model was US$141,942, while the ST model was US$48,020. In the TA model, the CPCT was US$7.66 and the CPCTP was US$508.75, whereas in the ST model, they were US$25.02 and US$727.58, respectively. In the TA model, the biggest cost was SARS-CoV-2 antigen rapid detection tests (Ag-RDTs) at 61% (US$86,853), whereas in the ST model, it was personnel at 39% (US$18,592). In Kenya, the total cost was US$39,264 in the TA model and US$27,500 in the ST model. The TA CPCT was US$13.04 and the CPCTP was US$1,189.81, whereas in the ST model the costs were $125.00 and $1,250.01 respectively. In both models in Kenya, the biggest expenditure was personnel, at 45% ($17,696) of cost in TA and 56% ($15,267) in ST. In both countries, the TA model was more cost-effective. Conclusions: Implementation of the TA model is a more cost-effective approach to increase early identification of individuals with SARS-CoV-2 infection.

1 January 2025 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
PDF file
LMLucky Makonokaya
Lucky Makonokaya
MKMaggie Khumbanyiwa
Maggie Khumbanyiwa
LKLouiser U. Kalitera
Louiser U. Kalitera
RCRachel Chamanga
Rachel Chamanga
SDShalom Dunga
Shalom Dunga
TMThulani Maphosa
Thulani Maphosa
Background: Viral suppression (VS) rates in children on antiretroviral therapy (ART) are lower than in adults. We described the effect of enhanced adherence counselling (EAC) on VS among children with high HIV viral load accessing dolutegravir (DTG)-based ART in a programme setting in Malawi. Objectives: This study evaluated the proportion of children with high viral load on DTG-based ART who re-suppressed following EAC and factors associated with VS post-EAC. Method: We included all patients aged < 15 years with a high viral load result (> 1000 copies/mL) after taking DTG-based ART for at least 6 months between January 2022 and March 2023, covering 104 healthcare facilities in Malawi. Descriptive statistics summarised the distribution of demographic and clinical characteristics. Multivariable logistic regression determined the factors associated with VS following EAC. Results: Overall, 1475 participants were enrolled; 884 (59.9%) were aged 10–14 years. A total of 1448 (98.2%) were enrolled in EAC, of whom 787 (54.3%), 308 (21.3%), and 353 (24.4%) completed three, two, and one session(s), respectively. Follow-up HIV viral load results were available for 1091 (74%) participants enrolled in EAC, and 782 (71.7%) achieved VS. Patients from urban areas were less likely to achieve VS post-EAC than those from rural areas (adjusted odds ratio [aOR]: 0.58, 95% confidence interval [CI]: 0.42–0.80). Conclusion: Nearly three-quarters of children with high viral load on DTG-based regimens achieved VS following EAC. Further research on the other contributors of virologic failure among children in Malawi is required.

1 January 2025 in Southern African Journal of HIV Medicine
Verified
Journal Article
Open access
LMLucky Makonokaya
Lucky Makonokaya
PNPatrick Ngwira
Patrick Ngwira
LKLouiser U. Kalitera
Louiser U. Kalitera
GSGeoffrey C. Singini
Geoffrey C. Singini
MKMaggie Khumbanyiwa
Maggie Khumbanyiwa
NBNilesh B. Bhatt
Nilesh B. Bhatt
Background: Tuberculosis preventive treatment (TPT) is recommended for people living with HIV (PLHIV) to reduce the tuberculosis (TB) incidence in regions with a high prevalence of TB. We evaluated the uptake and completion of TPT among newly initiated antiretroviral therapy (ART) patients in a programme setting in Malawi. Objectives: To describe TPT initiation and completion rates, and explore factors associated with TPT initiation and completion among newly initiated ART patients. Method: We conducted a retrospective cohort study analysing routinely collected data from 10 ART facilities. We included all patients who initiated ART between January 2023 and March 2023, with follow-up for 12 months. We used descriptive statistics to summarise demographic and clinical characteristics, and logistic regression to assess factors associated with TPT initiation and completion. Results: A total of 1289 patients were enrolled; 1015 (78.7%) were eligible for TPT. Of these, 820 (80.8%) initiated TPT; 610 (74.4%) completed treatment. Children (< 10 years), adolescents (10–19 years), patients presenting with WHO HIV clinical stage three or four conditions, and urban residents were less likely to initiate TPT: adjusted odds ratio (aOR) 0.12 (95% confidence interval [CI] 0.06–0.22), aOR 0.30 (95% CI 0.15–0.59), aOR 0.35 (95% CI 0.21–0.60), and aOR 0.56 (95% CI 0.34–0.90), respectively. Patients who received daily isoniazid for 6 months had reduced odds of completing TPT (aOR 0.22; 95% CI 0.11–0.42) compared with weekly isoniazid plus rifapentine for 3 months. Conclusion: High TPT initiation and completion rates were observed among eligible patients initiating ART in Malawi. However, children lag in TPT initiation. Targeted interventions that improve TPT uptake among paediatric patients are required.